Stromal fibroblasts shape the myeloid phenotype in normal colon and colorectal cancer and induce CD163 and CCL2 expression in macrophages

Colorectal cancer (CRC) accounts for about 10% of cancer deaths worldwide. Colon carcinogenesis is critically influenced by the tumor microenvironment. Cancer associated fibroblasts (CAFs) and tumor associated macrophages (TAMs) represent the major components of the tumor microenvironment. TAMs promote tumor progression, angiogenesis and tissue remodeling. However, the impact of the molecular crosstalk of tumor cells (TCs) with CAFs and macrophages on monocyte recruitment and their phenotypic conversion is not known in detail so far. In a 3D human organotypic CRC model, we show that CAFs and normal colonic fibroblasts are critically involved in monocyte recruitment and for the establishment of a macrophage phenotype, characterized by high CD163 expression. This is in line with the steady recruitment and differentiation of monocytes to immunosuppressive macrophages in the normal colon. Cytokine profiling revealed that CAFs produce M-CSF, and IL6, IL8, HGF and CCL2 secretion was specifically induced by CAFs in co-cultures with macrophages. Moreover, macrophage/CAF/TCs co-cultures increased TC invasion. We demonstrate that CAFs and macrophages are the major producers of CCL2 and, upon co-culture, increase their CCL2 production twofold and 40-fold, respectively. CAFs and macrophages expressing high CCL2 were also found in vivo in CRC, strongly supporting our findings. CCL2, CCR2, CSF1R and CD163 expression in macrophages was dependent on active MCSFR signaling as shown by M-CSFR inhibition. These results indicate that colon fibroblasts and not TCs are the major cellular component, recruiting and dictating the fate of infiltrated monocytes towards a specific macrophage population, characterized by high CD163 expression and CCL2 production

MISpheroID: a knowledgebase and transparency tool for minimum information in spheroid identity

Spheroids are three-dimensional cellular models with widespread basic and translational application across academia and industry. However, methodological transparency and guidelines for spheroid research have not yet been established. The MISpheroID Consortium developed a crowdsourcing knowledgebase that assembles the experimental parameters of 3,058 published spheroid-related experiments. Interrogation of this knowledgebase identified heterogeneity in the methodological setup of spheroids. Empirical evaluation and interlaboratory validation of selected variations in spheroid methodology revealed diverse impacts on spheroid metrics. To facilitate interpretation, stimulate transparency and increase awareness, the Consortium defines the MISpheroID string, a minimum set of experimental parameters required to report spheroid research. Thus, MISpheroID combines a valuable resource and a tool for three-dimensional cellular models to mine experimental parameters and to improve reproducibility. © 2021, The Author(s)

Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition

Colorectal cancer (CRC) is the second deadliest cancer in the world. Besides APC and p53 alterations, the PI3K/AKT/MTOR and MAPK pathway are most commonly mutated in CRC. So far, no treatment options targeting these pathways are available in routine clinics for CRC patients. We systematically analyzed the response of CRC cells to the combination of small molecular inhibitors targeting the PI3K and MAPK pathways. We used CRC cells in 2D, 3D spheroid, collagen gel cultures and freshly isolated organoids for drug response studies. Readout for drug response was spheroid or organoid growth, spheroid outgrowth, metabolic activity, Western blotting and immunofluorescence. We found profound tumor cell destruction under treatment with a combination of Torin 1 (inhibiting mTOR), MK2206 (targeting AKT) and selumetinib (inhibiting MEK) in 3D but not in 2D. Induction of cell death was due to apoptosis. Western blot analysis revealed efficient drug action. Gedatolisib, a dual PI3K/mTOR inhibitor, could replace Torin1/MK2206 with similar efficiency. The presence of PI3K and/or RAS-RAF-MAPK pathway mutations accounted for treatment responsiveness. Here, we identified a novel, efficient therapy, which induced proliferation stop and tumor cell destruction in vitro based on the genetic background. These preclinical findings show promise to further test this combi-treatment in vivo in mice and to potentially develop a mutation specific targeted therapy for CRC patients

MISpheroID: a knowledgebase and transparency tool for minimum information in spheroid identity

none51siSpheroids are three-dimensional cellular models with widespread basic and translational application across academia and industry. However, methodological transparency and guidelines for spheroid research have not yet been established. The MISpheroID Consortium developed a crowdsourcing knowledgebase that assembles the experimental parameters of 3,058 published spheroid-related experiments. Interrogation of this knowledgebase identified heterogeneity in the methodological setup of spheroids. Empirical evaluation and interlaboratory validation of selected variations in spheroid methodology revealed diverse impacts on spheroid metrics. To facilitate interpretation, stimulate transparency and increase awareness, the Consortium defines the MISpheroID string, a minimum set of experimental parameters required to report spheroid research. Thus, MISpheroID combines a valuable resource and a tool for three-dimensional cellular models to mine experimental parameters and to improve reproducibility.openPeirsman A.; Blondeel E.; Ahmed T.; Anckaert J.; Audenaert D.; Boterberg T.; Buzas K.; Carragher N.; Castellani G.; Castro F.; Dangles-Marie V.; Dawson J.; De Tullio P.; De Vlieghere E.; Dedeyne S.; Depypere H.; Diosdi A.; Dmitriev R.I.; Dolznig H.; Fischer S.; Gespach C.; Goossens V.; Heino J.; Hendrix A.; Horvath P.; Kunz-Schughart L.A.; Maes S.; Mangodt C.; Mestdagh P.; Michlikova S.; Oliveira M.J.; Pampaloni F.; Piccinini F.; Pinheiro C.; Rahn J.; Robbins S.M.; Siljamaki E.; Steigemann P.; Sys G.; Takayama S.; Tesei A.; Tulkens J.; Van Waeyenberge M.; Vandesompele J.; Wagemans G.; Weindorfer C.; Yigit N.; Zablowsky N.; Zanoni M.; Blondeel P.; De Wever O.Peirsman A.; Blondeel E.; Ahmed T.; Anckaert J.; Audenaert D.; Boterberg T.; Buzas K.; Carragher N.; Castellani G.; Castro F.; Dangles-Marie V.; Dawson J.; De Tullio P.; De Vlieghere E.; Dedeyne S.; Depypere H.; Diosdi A.; Dmitriev R.I.; Dolznig H.; Fischer S.; Gespach C.; Goossens V.; Heino J.; Hendrix A.; Horvath P.; Kunz-Schughart L.A.; Maes S.; Mangodt C.; Mestdagh P.; Michlikova S.; Oliveira M.J.; Pampaloni F.; Piccinini F.; Pinheiro C.; Rahn J.; Robbins S.M.; Siljamaki E.; Steigemann P.; Sys G.; Takayama S.; Tesei A.; Tulkens J.; Van Waeyenberge M.; Vandesompele J.; Wagemans G.; Weindorfer C.; Yigit N.; Zablowsky N.; Zanoni M.; Blondeel P.; De Wever O